Valuation : Genexine, Inc.

Market Cap 243B 179M 154M 144M 132M 247M 16.91B 249M 1.71B 665M 8.64B 672M 657M 27.83B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 181M 156M 146M 134M 250M 17.12B 252M 1.73B 674M 8.75B 680M 665M 28.17B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-16 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
01/10/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
23/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
01/10/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
26/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/10/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/08/23 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+15.81%
1 week+10.51%
Current month+23.25%
1 month+32.25%
3 months-6.72%
6 months-25.40%
Current year-30.42%
1 week 2,545
Extreme 2545
3,630
1 month 2,415
Extreme 2415
3,880
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
11,870
5 years 2,140
Extreme 2140
60,615.38
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 26/03/2025
Chief Executive Officer 61 27/01/2023
Corporate Officer/Principal 49 01/01/2022
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 29/03/2022
Director/Board Member 61 27/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/10/24 Others 156,632 0.3773%
22/10/24 Others

Chief Executive Officer

1,691,165 4.0741%
22/10/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
+15.81%+10.51%-36.82%-66.60% 94.27M
+0.41%-1.65%+39.85%+95.40% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.04%+1.84%-12.81%+459.54% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.90%-8.60%+2.25%-15.50% 26.08B
+1.01%+1.76%+32.99%-17.16% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.03%+5.40%+59.04%+160.03% 14.5B
Average +2.59%-0.27%+40.18%+166.03% 28.04B
Weighted average by Cap. +0.98%-1.63%+43.41%+149.90%

Financials

2022 2023
Net sales 16.14B 11.89M 10.23M 9.6M 8.78M 16.39M 1.12B 16.52M 114M 44.22M 574M 44.64M 43.67M 1.85B 4.43B 3.26M 2.81M 2.63M 2.41M 4.5M 308M 4.53M 31.14M 12.13M 158M 12.24M 11.98M 507M
Net income -55.97B -41.23M -35.48M -33.29M -30.46M -56.85M -3.9B -57.3M -394M -153M -1.99B -155M -151M -6.41B -66.87B -49.26M -42.38M -39.77M -36.39M -67.92M -4.66B -68.46M -471M -183M -2.38B -185M -181M -7.66B
Net Debt 62.14B 45.77M 39.38M 36.96M 33.81M 63.11M 4.33B 63.61M 437M 170M 2.21B 172M 168M 7.12B 2.94B 2.17M 1.87M 1.75M 1.6M 2.99M 205M 3.01M 20.72M 8.07M 105M 8.15M 7.97M 338M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
03/09/26 ₩3,260.00 +15.81% 3,331,659
02/09/26 ₩2,815.00 -6.48% 351,736
01/09/26 ₩3,010.00 +13.80% 1,341,470
31/08/26 ₩2,645.00 -3.29% 221,151
28/08/26 ₩2,735.00 -0.73% 164,089
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock